Ramot at Tel Aviv University has signed an agreement with Neurimmune to fund the development of a novel approach to treat Alzheimer’s disease (AD). The Agreement also includes pre-negotiated licensing terms for future ApoE4-based products.
The aim of the collaboration is to develop anti-Apolipoprotein E4 (ApoE4) antibodies for the treatment of AD and related neurodegenerative diseases. ApoE4 is the most prevalent genetic risk factor for Alzheimer's disease. The incidence of ApoE4 in AD is greater than 50% and increases the risk for the disease by lowering the age of onset by 7 to 9 years. Anti-ApoE4 antibodies are expected to neutralize the toxicity of ApoE4 or to stimulate its removal.
The research by Prof. Daniel Michaelson from the Department of Neurobiology, The George S. Wise Faculty of Life Sciences at Tel Aviv University, focuses on unraveling the basic cellular and molecular mechanisms underlying neurodegeneration in Alzheimer's disease, and the development of novel therapeutic approaches to counteract them.
About Ramot at Tel Aviv University
Ramot is the technology transfer company of Tel Aviv University. Ramot fosters, initiates, leads and manages the transfer of new technologies from university laboratories to the marketplace by performing all activities relating to the protection and commercialization of inventions and discoveries made by faculty, students and other researchers. Ramot provides a dynamic interface connecting industry to leading-edge science and innovation, offering new business opportunities in a broad range of emerging markets .
0Comments
Please login or sign up to comment.
Commenting guidelines